JP2021529520A5 - - Google Patents

Info

Publication number
JP2021529520A5
JP2021529520A5 JP2020572914A JP2020572914A JP2021529520A5 JP 2021529520 A5 JP2021529520 A5 JP 2021529520A5 JP 2020572914 A JP2020572914 A JP 2020572914A JP 2020572914 A JP2020572914 A JP 2020572914A JP 2021529520 A5 JP2021529520 A5 JP 2021529520A5
Authority
JP
Japan
Prior art keywords
antibody
acid sequence
amino acid
seq
hvr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020572914A
Other languages
English (en)
Japanese (ja)
Other versions
JP7575278B2 (ja
JP2021529520A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/039757 external-priority patent/WO2020006374A2/en
Publication of JP2021529520A publication Critical patent/JP2021529520A/ja
Publication of JP2021529520A5 publication Critical patent/JP2021529520A5/ja
Priority to JP2024071229A priority Critical patent/JP2024119792A/ja
Application granted granted Critical
Publication of JP7575278B2 publication Critical patent/JP7575278B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020572914A 2018-06-29 2019-06-28 抗sirp-ベータ1抗体及びその使用方法 Active JP7575278B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024071229A JP2024119792A (ja) 2018-06-29 2024-04-25 抗sirp-ベータ1抗体及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862691913P 2018-06-29 2018-06-29
US62/691,913 2018-06-29
PCT/US2019/039757 WO2020006374A2 (en) 2018-06-29 2019-06-28 Anti-sirp-beta1 antibodies and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024071229A Division JP2024119792A (ja) 2018-06-29 2024-04-25 抗sirp-ベータ1抗体及びその使用方法

Publications (3)

Publication Number Publication Date
JP2021529520A JP2021529520A (ja) 2021-11-04
JP2021529520A5 true JP2021529520A5 (enExample) 2022-07-06
JP7575278B2 JP7575278B2 (ja) 2024-10-29

Family

ID=67439371

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020572914A Active JP7575278B2 (ja) 2018-06-29 2019-06-28 抗sirp-ベータ1抗体及びその使用方法
JP2024071229A Pending JP2024119792A (ja) 2018-06-29 2024-04-25 抗sirp-ベータ1抗体及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024071229A Pending JP2024119792A (ja) 2018-06-29 2024-04-25 抗sirp-ベータ1抗体及びその使用方法

Country Status (14)

Country Link
US (2) US12060422B2 (enExample)
EP (1) EP3814377A2 (enExample)
JP (2) JP7575278B2 (enExample)
KR (1) KR20210025614A (enExample)
CN (2) CN112384532B (enExample)
AU (1) AU2019293589A1 (enExample)
BR (1) BR112020026819A2 (enExample)
CA (1) CA3099176A1 (enExample)
EA (1) EA202190138A1 (enExample)
IL (1) IL279648A (enExample)
MA (1) MA53015A (enExample)
MX (1) MX2020013324A (enExample)
SG (1) SG11202010990TA (enExample)
WO (1) WO2020006374A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016286108B2 (en) 2015-06-30 2021-03-11 Pfizer Inc. BTLA fusion protein agonists and uses thereof
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
CA3176425A1 (en) * 2020-04-24 2021-10-28 Millennium Pharmaceuticals, Inc. Anti-cd19 antibodies and uses thereof
CN116063473B (zh) * 2020-05-19 2026-06-09 益科思特(北京)医药科技发展有限公司 抗新型冠状病毒Spike蛋白抗体及其应用
WO2022115350A1 (en) * 2020-11-30 2022-06-02 Merck Sharp & Dohme Corp. Arginase 1 binders for inhibiting arginase 1 activity
EP4255451A4 (en) * 2020-12-03 2025-01-01 The Board Of Regents Of The University Of Texas System Methods for identifying lilrb-blocking antibodies
CA3231484A1 (en) 2021-10-01 2023-04-06 Qinwen Mao Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy
CN114478802B (zh) * 2022-01-28 2023-05-26 郑州大学 一种嵌合抗原受体及其应用
WO2024105180A1 (en) 2022-11-16 2024-05-23 Boehringer Ingelheim International Gmbh Predictive efficacy biomarkers for anti-sirpa antibodies
AU2024231916A1 (en) * 2023-03-09 2025-10-02 Triveni Bio, Inc. Dual inhibitor kallikrein antibodies and uses thereof
AU2024333809A1 (en) * 2023-08-25 2026-02-26 Triveni Bio, Inc. Klk5/7 + th2 targeting antibodies and uses thereof
AU2024331904A1 (en) * 2023-08-25 2026-03-12 Triveni Bio, Inc. Klk5/7 + il-13 targeting antibodies and uses thereof
WO2025049347A1 (en) * 2023-08-25 2025-03-06 Triveni Bio, Inc. Klk5/7 + il-4 targeting antibodies and uses thereof
WO2025101471A1 (en) * 2023-11-09 2025-05-15 Merck Sharp & Dohme Llc Anti-cd27 antibody cell-based biological potency assay
WO2025166146A1 (en) * 2024-02-02 2025-08-07 Triveni Bio, Inc. Klk5/7 + ox40 targeting antibodies and uses thereof
WO2025166138A1 (en) * 2024-02-02 2025-08-07 Triveni Bio, Inc. Klk5/7 + tslp targeting antibodies and uses thereof
WO2026060000A1 (en) * 2024-09-11 2026-03-19 Triveni Bio, Inc. Dual inhibitor kallikrein antibodies and uses thereof

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
WO1997011971A1 (en) 1995-09-28 1997-04-03 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
EP1244707A1 (de) 1999-11-30 2002-10-02 Eberhard-Karls-Universität Tübingen Universitätsklinikum Antikörper gegen signal-regulator-proteine
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
KR20050000380A (ko) 2002-04-09 2005-01-03 교와 핫꼬 고교 가부시끼가이샤 게놈이 개변된 세포
CA2481920A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
WO2003085102A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
JP4224586B2 (ja) * 2004-04-28 2009-02-18 国立大学法人群馬大学 マクロファージ活性化剤並びにその製造方法及びスクリーニング方法
MY146381A (en) * 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
HUE066795T2 (hu) 2006-03-15 2024-09-28 Alexion Pharma Inc Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral
EP2016101A2 (en) 2006-05-09 2009-01-21 Genentech, Inc. Binding polypeptides with optimized scaffolds
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
WO2009036379A2 (en) 2007-09-14 2009-03-19 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
CN101880324B (zh) 2010-05-25 2012-10-17 中国人民解放军第二军医大学 一种抗人SIRPα的单克隆抗体及其细胞株、制备方法和应用
MX381912B (es) 2010-07-16 2025-03-13 Adimab Llc Colecciones de anticuerpos.
LT2748201T (lt) 2011-08-23 2018-02-26 Roche Glycart Ag Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė
WO2013056352A1 (en) 2011-10-19 2013-04-25 University Health Network Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
US9175082B2 (en) * 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
HK1221908A1 (zh) 2013-04-29 2017-06-16 Adimab, Llc 多特异(polyspecificity)试剂,其制备方法和用途
WO2015138600A2 (en) 2014-03-11 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
GB201413357D0 (en) * 2014-07-28 2014-09-10 Philogen Spa Antibodies for treatment and diagnosis
TW201632559A (zh) * 2015-02-22 2016-09-16 索倫多醫療公司 結合cd137之抗體治療劑
CN115960235A (zh) 2015-08-28 2023-04-14 艾利妥 抗siglec-7抗体及其使用方法
AU2016332900C1 (en) * 2015-09-29 2024-07-04 Amgen Inc. ASGR inhibitors
PT3625259T (pt) * 2017-05-16 2024-07-04 Synthon Biopharmaceuticals Bv Anticorpos anti-sirpalfa

Similar Documents

Publication Publication Date Title
JP7862028B2 (ja) 免疫細胞活性化のための二重特異性抗体
CN110799539B (zh) 抗4-1bb抗体及其制备和使用方法
US11649286B2 (en) Tri-specific antibodies
Moore et al. Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma
JP2020532947A5 (enExample)
JP2020533948A5 (enExample)
US11787863B2 (en) Multi-specific antibodies and methods of making and using thereof
JP2018518176A5 (enExample)
JP2018525999A5 (enExample)
US12312409B2 (en) Bispecific CD137-binding antibodies for T-cell activation
JP2020500540A5 (enExample)
JP2018518491A5 (enExample)
CN117946278A (zh) 多特异性抗体及其制备和使用方法
CA3043656A1 (en) Combination of t-cell redirecting multifunctional antibodies with immune checkpoint modulators and uses thereof
TW202200618A (zh) 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法
Lindhofer et al. Trifunctional Triomab® antibodies for cancer therapy
HK40113078A (en) Anti-cd19 antibodies and methods of using and making thereof
JP2025087939A (ja) がん治療におけるpd-1シグナル阻害剤との組み合わせによる抗tspan8-抗cd3二重特異性抗体の使用
TH2101001911A (th) โมเลกุลที่เชื่อมต่อแอนติเจนชนิดไบสเปซิฟิก ซึ่งประกอบรวมด้วยโคลนสารต้าน fap212
HK40116546A (en) Immunomodulatory trispecific t cell engager fusion proteins
HK40019010A (en) Multi-specific antibodies and methods of making and using thereof